NKF

Yicai · Jul 28 at 05:28 AM

First China-Made Rapid-Acting Insulin Wins US FDA Approval

Zhitong · Oct 24, 2025 at 11:13 AM

NKF released its performance for the first three quarters, with a net profit attributable to the parent company of 429 million yuan, a year-on-year decrease of 29.11%

Zhitong · Oct 24, 2025 at 03:53 AM

NKF: Subsidiary Meitheal Pharmaceuticals Inc. received new drug injection registration approval from the U.S. FDA for phosphomycin

Zhitong · Sep 25, 2025 at 08:46 PM

NKF: Products exported to the U.S. are generic drugs, and the impact of tariffs needs further observation

Zhitong · Aug 28, 2025 at 08:51 AM

NKF released its semi-annual performance report, with a net profit attributable to the parent company of 286 million yuan, a year-on-year decrease of 29.32%

Zhitong · Jul 22, 2025 at 03:29 AM

NKF's subsidiary has obtained the US FDA's registration approval for the transfer of the production site of Etoposide Injection